The role of dosimetry and biological effects in metastatic castration–resistant prostate cancer (mCRPC) patients treated with 223Ra: first in human study

Table. 1 Patients’ characteristics at study entry

Pt #	Age	Weight	GleasonScore	PSA	ALP	ECOG status	N. of BoneMets	Haemoglobin level	Testosteronlevel	BM delay	PreviousTreatment
	(Yrs)	(Kg)		(ng/ml)	(U/L)			(g /dl)	(ng/ml)	(months)
1	84	97	9	3.82	51	0	2	13.60	0.03	116	RT
2	72	72	7	42.30	59	2	> 20	13.20	0.03	48	ABI-ENZA
3	78	78	7	1161	170	2	> 20	12.80	0.03	48	ABICT (1 line)
4	60	60	9	757.00	418	2	10–20	10.40	0.03	18	ABI-ENZARTCT (2 lines)
5	60	60	7	6.74	89	0	4	15.80	0.09	0	ABI - ENZA

Legend: ECOG Eastern Cooperative Oncology Group, BM delay time from initial prostate cancer diagnosis to bone metastases diagnosis, ABI abiraterone, ENZA enzatulamide, CT chemotherapy, RT bone targeted radiotherapy, PSA prostate-specific antigen, ALP alkaline phosphatase

ISSN: 1756-9966